USPTO serial 87729142
GLYXIA
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- KAJUBI, ELIZABETH N
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with GLYXIA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Monica Riva Talley
Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C.1100 New York Avenue, N.W.Washington, DC 20005UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post-intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Biohaven Pharmaceutical Holding Company Limited
- Other trademarks owned by Biohaven Pharmaceutical Holding Company Limited
- Other trademarks in Class 005
- Similar marks named GLYXIA
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 31, 2022 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jan 31, 2022 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 24, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 23, 2021 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Jun 21, 2021 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jun 21, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 23, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 21, 2020 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Dec 21, 2020 | EXT4 | SOU EXTENSION 4 FILED | — |
| Dec 21, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 1, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 30, 2020 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jun 30, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jun 17, 2020 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jun 17, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 3, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 3, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 13, 2020 | WOAG | WITHDRAWAL OF ATTORNEY GRANTED | — |
| Jan 13, 2020 | WOAR | TEAS WITHDRAWAL OF ATTORNEY RECEIVED | — |
| Dec 21, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 19, 2019 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Dec 19, 2019 | EXT2 | SOU EXTENSION 2 FILED | — |
| Dec 19, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 23, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 23, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 5, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 3, 2019 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jun 3, 2019 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jun 3, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 25, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 30, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 30, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 10, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 21, 2018 | ALIE | ASSIGNED TO LIE | — |
| Sep 6, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 31, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 30, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 30, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 29, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 29, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 29, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 27, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 8, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 23, 2017 | NWAP | NEW APPLICATION ENTERED | — |